Efficacy

Efficacy of Phesgo in Breast Cancer

Phesgo is a combination medication that includes pertuzumab, trastuzumab, and hyaluronidase-zzxf. It is used for the treatment of HER2-positive breast cancer, which is a type of breast cancer characterized by an overexpression of the HER2 protein. Clinical trials have demonstrated that the combination of pertuzumab and trastuzumab, when used with chemotherapy, significantly improves progression-free survival and overall survival in patients with metastatic HER2-positive breast cancer. Phesgo is designed to be administered subcutaneously, providing a more convenient alternative to the intravenous formulations of pertuzumab and trastuzumab.

The efficacy of Phesgo has been evaluated in a pivotal study known as the FeDeriCa trial, which confirmed non-inferior levels of pertuzumab in the blood and comparable efficacy to the intravenous formulation when given with chemotherapy. The study also showed that the fixed-dose combination of Phesgo was effective in achieving a complete response in a significant number of patients with early breast cancer. The safety profile of Phesgo was found to be consistent with the known safety profiles of intravenous pertuzumab and trastuzumab.

Efficacy of Capivasertib (Truqap) in Breast Cancer

Capivasertib, also known by its development name AZD5363 and referred to as Truqap in some contexts, is an investigational drug that targets the AKT signaling pathway, which is implicated in the growth and survival of cancer cells. It is being studied for its potential use in treating various types of cancers, including breast cancer. In breast cancer, capivasertib has been evaluated in combination with other therapies, such as fulvestrant, in patients with advanced or metastatic hormone receptor-positive breast cancer that is also AKT1 E17K mutation-positive.

Initial studies have shown that capivasertib, when used in combination with fulvestrant, has improved progression-free survival in patients with this subtype of breast cancer. The efficacy of capivasertib is particularly notable in patients whose tumors harbor the AKT1 E17K mutation, suggesting that it may offer a targeted treatment approach for this group. However, as capivasertib is still under investigation, further clinical trials are required to fully establish its efficacy and safety profile in the treatment of breast cancer.